Clinical Research Directory
Browse clinical research sites, groups, and studies.
Breast Cancer PSMA PET
Sponsor: Ahmad Shariftabrizi
Summary
The purpose of this research is to determine the expression of Prostate Specific Membrane Antigen(PSMA) in metastatic Triple Negative Breast Cancer (TNBC) patients using Fludeoxyglucose F18 (FDG) PET/CT as the gold standard. The investigators hypothesize that most lesions in metastatic TNBC are PSMA-avid; and thus PSMA-based radionuclide therapy can be a valid treatment option for TNBC, and clinical trials can be designed for this purpose. Thirty metastatic TNBC patients will be enrolled and will be on the study for maximum of 4 weeks.
Official title: Evaluation of PSMA Expression in Triple Negative Breast Cancer Patients Using 18 F-DCFPyL-PET/CT
Key Details
Gender
FEMALE
Age Range
18 Years - 90 Years
Study Type
INTERVENTIONAL
Enrollment
30
Start Date
2024-08-29
Completion Date
2026-12-29
Last Updated
2026-03-27
Healthy Volunteers
No
Conditions
Interventions
PET imaging
Imaging with FDG PET/CT and Pyl PET/CT in triple negative breast cancer
Locations (1)
University of Iowa Healthcare
Iowa City, Iowa, United States